ArticleEndocrine oncology (Bristol, England)2025
Epidemiology, presentation and outcomes in pituitary apoplexy: a population-based study in Malta.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims and objectives: To determine the prevalence, incidence, and outcomes of pituitary apoplexy patients presenting acutely in Malta. Methodology: Twenty-nine patients presenting with pituitary apoplexy between 1980 and 2023 were retrospectively identified. The prevalence and incidence rates were calculated. The clinical presentation, endocrinological and radiological findings, and outcomes of all patients with pituitary apoplexy were analysed and compared between the two cohorts who were treated conservatively or with early surgical intervention, taking into consideration serum prolactin levels at diagnosis. The pituitary apoplexy score was applied retrospectively. Results: Five of the 29 patients had a known pituitary adenoma. The prevalence for pituitary apoplexy was 4.61/100,000 individuals (NFPA 3.69/100,000; functional adenoma 0.92/100,000), and the overall SIR was 0.189/100,000/year (NFPA 0.144/100,000/year; functional adenoma 0.047/100,000/year). Prevalence rates and SIR were higher among males (prevalence 8.08/100,000 in males vs 0.78/100,000 in females). Ninety-two percent of the patients who presented with apoplexy were macroadenomas, while 8% were microadenomas. The median age for apoplexy was found to be 51 years (42-58); higher in the NFPA subtype, 55 (49.5-63) when compared to 43 (38.5-45.25) in the functional group. Visual field defects were more prevalent when baseline prolactin levels were less than 5 ng/mL, 68.75 vs 42.86% ( Conclusion: Through thorough case identification, this study provides both prevalence and incidence rates of pituitary apoplexy in a well-defined population in Malta. Clinical sequelae and various treatment modalities have been studied to better understand this rare condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.